Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2021-08-02 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT MHRA APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101 IN THE UNITED KINGDOM
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval received from the MHRA for a Phase III clinical trial of their drug OT-101. It provides business updates about the clinical trial progress and regulatory approvals but does not contain financial statements, detailed financial analysis, or regulatory certifications. The document is relatively short (4070 characters) and serves as an update to shareholders and investors about a specific business development rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of a business event related to clinical trial approval, which aligns best with a general Regulatory Filings (RNS) category as a miscellaneous regulatory/business update announcement that does not fit other specific categories.
2021-08-02 English
List of Directors and their Role and Function
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles, as well as the membership of board committees such as Audit, Remuneration, and Nomination Committees. There is no financial data, no mention of a report or meeting, and no indication of changes in management or shareholding. The content is focused on governance structure and board composition. This fits the definition of Board/Management Information (MANG), which covers announcements about the company's board of directors or senior management.
2021-07-20 English
RE-DESIGNATION OF EXECUTIVE DIRECTORS AS NON-EXECUTIVE DIRECTORS
Board/Management Information Classification · 95% confidence The document is an announcement from Ocumension Therapeutics regarding the re-designation of two executive directors as non-executive directors. It details the changes in board composition, biographies of the directors, and compliance with listing rules. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is 7180 characters, which is sufficient for a detailed announcement but does not constitute a full report like an annual or interim report. Therefore, the appropriate classification is MANG with high confidence.
2021-07-20 English
VOLUNTARY ANNOUNCEMENT CDE APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-101
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval received for a Phase III clinical trial of a drug (OT-101). It is an announcement of a business update related to clinical trial progress and regulatory approval, not a financial report or detailed management discussion. The document is relatively short (4022 characters) and serves to inform shareholders and investors about a specific event rather than providing comprehensive financial data or detailed report content. There is no indication of financial statements, audit information, or detailed governance disclosures. It is not a report publication announcement since it contains substantive content about the clinical trial approval. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and business update that does not fit into other specific categories such as earnings release, management report, or capital update.
2021-07-13 English
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF OT-502 APPROVED IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval of a Phase III clinical trial for a drug candidate OT-502 in China. It is an update on business progress and regulatory acceptance, not a financial report or detailed management discussion. The document is relatively short (3236 characters) and serves to inform shareholders and investors about a specific business development. There is no financial data, no mention of annual or quarterly results, no voting results, no board changes, no merger or acquisition activity, and no regulatory certification. It is clearly an announcement of a business event rather than a report or filing of financial or governance nature. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-07-08 English
VOLUNTARY ANNOUNCEMENT OT-502 APPROVED FOR URGENT MEDICAL NEEDS IN HAINAN
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the approval of their product OT-502 for urgent medical needs in Hainan. It is an update on business developments and regulatory approval status, not a financial report or detailed filing. The document is relatively short (2733 characters) and serves as a business update rather than a formal report or regulatory filing. There is no indication of financial data, management changes, voting results, or other specific report types. It is an announcement informing shareholders and investors about a product approval, which fits best under the category of a general regulatory or business update announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2021-07-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.